FY2025 EPS Estimates for AngioDynamics Increased by Analyst

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Equities researchers at Zacks Research increased their FY2025 earnings per share (EPS) estimates for AngioDynamics in a research report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of ($0.32) for the year, up from their prior forecast of ($0.38). The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics' Q4 2025 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.10) EPS and Q2 2027 earnings at ($0.06) EPS.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business had revenue of $72.00 million during the quarter, compared to analysts' expectations of $70.30 million. The business's quarterly revenue was down 4.3% on a year-over-year basis.

Separately, HC Wainwright reiterated a "buy" rating and set a $16.00 price objective (up previously from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Stock Performance

AngioDynamics stock traded down $0.20 during midday trading on Friday, reaching $9.38. 69,541 shares of the company were exchanged, compared to its average volume of 556,808. The company has a market capitalization of $380.89 million, a price-to-earnings ratio of -1.67 and a beta of 0.52. The firm's 50-day simple moving average is $9.52 and its 200-day simple moving average is $9.18. AngioDynamics has a 1 year low of $5.47 and a 1 year high of $13.50.

Institutional Trading of AngioDynamics

A number of hedge funds have recently added to or reduced their stakes in ANGO. State Street Corp boosted its stake in AngioDynamics by 2.7% in the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier's stock worth $6,305,000 after buying an additional 21,218 shares during the last quarter. Barclays PLC lifted its stake in shares of AngioDynamics by 81.0% in the 3rd quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier's stock valued at $651,000 after purchasing an additional 37,394 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of AngioDynamics by 5.1% in the 3rd quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier's stock valued at $7,477,000 after purchasing an additional 46,409 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of AngioDynamics by 28.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Finally, Moody National Bank Trust Division lifted its stake in shares of AngioDynamics by 70.2% in the 4th quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier's stock valued at $511,000 after purchasing an additional 23,003 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.